PE20040562A1 - Vacunas que comprenden mezclas de cepas meningococicas multivalentes - Google Patents

Vacunas que comprenden mezclas de cepas meningococicas multivalentes

Info

Publication number
PE20040562A1
PE20040562A1 PE2003000583A PE2003000583A PE20040562A1 PE 20040562 A1 PE20040562 A1 PE 20040562A1 PE 2003000583 A PE2003000583 A PE 2003000583A PE 2003000583 A PE2003000583 A PE 2003000583A PE 20040562 A1 PE20040562 A1 PE 20040562A1
Authority
PE
Peru
Prior art keywords
heterological
meningococcal
multivalent meningococcal
meningococcal strains
deficient
Prior art date
Application number
PE2003000583A
Other languages
English (en)
Spanish (es)
Inventor
Morales Ramon Faustino Barbera
Alvarez Francisco Jesus Dominguez
Pierre Michel Desmons
Jan Poolman
Original Assignee
Glaxosmithkline Biolog Sa
Inst Finlay Ct De Investigacion Produccion De Sueros Y Vacunas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa, Inst Finlay Ct De Investigacion Produccion De Sueros Y Vacunas filed Critical Glaxosmithkline Biolog Sa
Publication of PE20040562A1 publication Critical patent/PE20040562A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PE2003000583A 2002-06-13 2003-06-11 Vacunas que comprenden mezclas de cepas meningococicas multivalentes PE20040562A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0213622.4A GB0213622D0 (en) 2002-06-13 2002-06-13 Vaccine Corporation

Publications (1)

Publication Number Publication Date
PE20040562A1 true PE20040562A1 (es) 2004-10-19

Family

ID=9938532

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000583A PE20040562A1 (es) 2002-06-13 2003-06-11 Vacunas que comprenden mezclas de cepas meningococicas multivalentes

Country Status (20)

Country Link
US (1) US20060110412A1 (https=)
EP (1) EP1565211A2 (https=)
JP (1) JP2005531614A (https=)
KR (1) KR20050049431A (https=)
CN (1) CN100387298C (https=)
AR (1) AR040204A1 (https=)
AU (1) AU2003236734A1 (https=)
BR (1) BR0311777A (https=)
CA (1) CA2488782A1 (https=)
CL (1) CL2003001192A1 (https=)
CU (1) CU23552A1 (https=)
GB (1) GB0213622D0 (https=)
MX (1) MXPA04012568A (https=)
NO (1) NO20050132L (https=)
NZ (1) NZ560766A (https=)
PE (1) PE20040562A1 (https=)
RU (1) RU2005100509A (https=)
UY (1) UY27843A1 (https=)
WO (1) WO2003105890A2 (https=)
ZA (1) ZA200409547B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2519440T3 (es) 2000-07-27 2014-11-07 Children's Hospital & Research Center At Oakland Vacunas para la protección de amplio espectro contra enfermedades causadas por Neisseria meningitidis
GB2414667A (en) * 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
WO2006081259A2 (en) 2005-01-27 2006-08-03 Children's Hospital & Research Center At Oakland Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
KR101515078B1 (ko) * 2005-12-22 2015-04-24 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
JP5814507B2 (ja) 2006-09-07 2015-11-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
BR122016015627A2 (pt) 2007-10-19 2018-10-30 Novartis Ag kit, composição antigênica liofilizada e método para preparação de uma composição imunogênica
JP2011503104A (ja) 2007-11-09 2011-01-27 カリフォルニア インスティテュート オブ テクノロジー 免疫調節化合物ならびに関連組成物および方法
EP2235531B1 (en) * 2008-02-01 2015-01-14 Sanofi Pasteur Limited Assay for diagnosing streptococcus pneumoniae
CN102015651B (zh) 2008-03-03 2014-12-31 Irm责任有限公司 作为tlr活性调节剂的化合物和组合物
WO2010070453A2 (en) 2008-12-17 2010-06-24 Novartis Ag Meningococcal vaccines including hemoglobin receptor
JP5867952B2 (ja) 2009-06-10 2016-02-24 ノバルティス アーゲー ベンゾナフチリジン含有ワクチン
EP2470205A1 (en) 2009-08-27 2012-07-04 Novartis AG Adjuvant comprising aluminium, oligonucleotide and polycation
WO2011027222A2 (en) 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
EP2486940B1 (en) * 2009-10-08 2017-10-04 Aeon Medix Inc. Composition comprising extracellular membrane vesicles derived from indoor air, and use thereof
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
BR112012014624A8 (pt) 2009-12-15 2017-12-26 Novartis Ag suspensão homogênea de compostos de imunopotenciação e usos dos destes
AU2010335970B2 (en) * 2009-12-22 2016-11-03 Sanofi Pasteur Limited Immunogenic compositions
AU2011288203A1 (en) 2010-03-18 2012-08-23 Novartis Ag Adjuvanted vaccines for serogroup B meningococcus
EA031379B1 (ru) 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
JP6027961B2 (ja) 2010-04-07 2016-11-16 シェン, ユエSHEN, Yue 粘膜へ化合物を送るための媒体、それに関連する組成物、方法、及びシステム
US9259462B2 (en) * 2010-09-10 2016-02-16 Glaxosmithkline Biologicals Sa Developments in meningococcal outer membrane vesicles
US20150147356A1 (en) 2011-05-12 2015-05-28 Alan Kimura Antipyretics to enhance tolerability of vesicle-based vaccines
US9539281B2 (en) 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
EP3299467B1 (en) 2012-02-02 2021-08-11 GlaxoSmithKline Biologicals SA Promoters for increased protein expression in meningococcus
US10598666B2 (en) 2012-03-08 2020-03-24 Glaxosmithkline Biologicals Sa In vitro potency assay for protein-based meningococcal vaccines
AU2013276083B2 (en) 2012-06-14 2018-04-05 Institut Pasteur Vaccines for serogroup X meningococcus
JP6324961B2 (ja) 2012-09-06 2018-05-16 ノバルティス アーゲー 血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
JP6918365B2 (ja) 2015-08-19 2021-08-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 脂質化ｐｓａ組成物および方法
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use
US12109259B2 (en) 2016-09-02 2024-10-08 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
MX2023004729A (es) * 2020-10-23 2023-06-29 Omvax Inc Composiciones y metodos de vacunacion contra neisseria gonorrhoeae.
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2297072A1 (en) * 1997-07-17 1999-01-28 Baxter Healthcare S.A. Immunogenic conjugates comprising a group b meningococcal porin and an h. influenzae polysaccharide
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
ES2519440T3 (es) * 2000-07-27 2014-11-07 Children's Hospital & Research Center At Oakland Vacunas para la protección de amplio espectro contra enfermedades causadas por Neisseria meningitidis

Also Published As

Publication number Publication date
NZ560766A (en) 2009-09-25
KR20050049431A (ko) 2005-05-25
BR0311777A (pt) 2005-03-29
GB0213622D0 (en) 2002-07-24
UY27843A1 (es) 2003-12-31
NO20050132L (no) 2005-02-11
CN100387298C (zh) 2008-05-14
AU2003236734A1 (en) 2003-12-31
MXPA04012568A (es) 2005-09-21
US20060110412A1 (en) 2006-05-25
AR040204A1 (es) 2005-03-16
JP2005531614A (ja) 2005-10-20
EP1565211A2 (en) 2005-08-24
CU23552A1 (es) 2010-07-20
CL2003001192A1 (es) 2005-01-07
CA2488782A1 (en) 2003-12-24
CN1668329A (zh) 2005-09-14
WO2003105890A2 (en) 2003-12-24
NO20050132D0 (no) 2005-01-11
ZA200409547B (en) 2006-07-26
RU2005100509A (ru) 2006-06-10
WO2003105890A3 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
PE20040562A1 (es) Vacunas que comprenden mezclas de cepas meningococicas multivalentes
BR0315228A (pt) vacinas de polipeptìdeo para ampla proteção contra linhagens meningocócicas hipervirulentas
AR061333A1 (es) Composiciones de vacuna de la neisseria
BR0314943A (pt) Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes
BR0015961A (pt) Antìgeno de neisseria de 85kda
NO20080745L (no) Nye peptider for anvendelse i behandling av fedme
AR109170A2 (es) Esfingomielinasa ácida para uso en la prevención o el tratamiento de la enfermedad de niemann-pick a o b en un paciente
BR112014021658A2 (pt) composições de neisseria meningitidis e métodos das mesmas
UY27940A1 (es) Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-a
CL2020000491A1 (es) Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry.
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
DK117491A (da) Vaccine imod meningococcussygdomme, deri indgaaende komponenter, disses anvendelse og rekombinanter, som eksprimerer dem
NO20073059L (no) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
CR10123A (es) Vacuna.
BRPI0410684A (pt) uso de um peptìdio conjugado a uma proteìna que age como um imunógeno para a produção de anticorpos capazes de reconhecer especificamente qualquer uma das variantes predominantes do peptìdeo beta amilóide aß40 e aß42 na preparação de um medicamento para a prevenção e/ou o tratamento de uma doença e uso de um anticorpo ou um fragmento ativo ou o derivado de um anticorpo que reconhece especificamente qualquer uma das variantes predominantes do peptìdio beta amilóide, aß40 e aß42, na preparação de um medicamento para prevenção e/ou tratamento de uma doença
BR0315319A (pt) Terapias e procedimentos dentais com toxina botulìnica
CY1106771T1 (el) Φαρμακευτικη συνθεση η οποια χρησιμοποιειται για τον ελεγχο της γλυκοζης του αιματος σε ασθενεις με διαβητη τυπου 2
BRPI0314373B8 (pt) produto imunogênico estável para a indução de anticorpos contra uma ou várias proteínas antigênicas em um indivíduo, composições farmacêutica, imunogênica e de vacina e processo de preparação de um produto imunogênico
BR112014012460A2 (pt) proteínas recombinantes e seus usos terapêuticos
MX2008004734A (es) Composicion rica en leucina.
ECSP044986A (es) Composicion farmaceutica que comprende lumiracoxib
ATE427737T1 (de) Mikroemulsionen von retinoiden und diese enthaltende pharmazeutische zusammensetzungen
NO20065835L (no) Medikamenter som inneholder N-sulfamoyl-N'-arylpiperaziner for profylakse eller behandling av overvekt og beslektede tilstander
AR054259A1 (es) Vacuna contra virus de papiloma humano (hpv)
BRPI0412506A (pt) células autólogas que induzem à autotoleráncia de origem monocìtica e seu uso em preparações farmacêuticos

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed